RAINFALL (NCT02314117), a phase III study, randomized 645 patients with HER2-nonexpressing advanced GC to receive cisplatin plus a fluoropyrimidine with ramucirumab (326 patients) or placebo (319 patients) as first-line treatment [66]. The gene discussed is ERBB2; the disease is gastric cancer.